NO921104L - Farmasoeytisk aktive preparater, fremgangsmaate for deres fremstilling og anvendelse derav - Google Patents

Farmasoeytisk aktive preparater, fremgangsmaate for deres fremstilling og anvendelse derav

Info

Publication number
NO921104L
NO921104L NO92921104A NO921104A NO921104L NO 921104 L NO921104 L NO 921104L NO 92921104 A NO92921104 A NO 92921104A NO 921104 A NO921104 A NO 921104A NO 921104 L NO921104 L NO 921104L
Authority
NO
Norway
Prior art keywords
optionally substituted
heterocyclic radical
alkyl
procedures
preparation
Prior art date
Application number
NO92921104A
Other languages
English (en)
Other versions
NO179171B (no
NO921104D0 (no
NO179171C (no
Inventor
Rudolf Karl Andreas Giger
Henri Mattes
Original Assignee
Sandoz Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26298625&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO921104(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB919106179A external-priority patent/GB9106179D0/en
Priority claimed from GB919107927A external-priority patent/GB9107927D0/en
Application filed by Sandoz Ag filed Critical Sandoz Ag
Publication of NO921104D0 publication Critical patent/NO921104D0/no
Publication of NO921104L publication Critical patent/NO921104L/no
Publication of NO179171B publication Critical patent/NO179171B/no
Publication of NO179171C publication Critical patent/NO179171C/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/58—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
    • C07F7/0814—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring said ring is substituted at a C ring atom by Si
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/572—Five-membered rings
    • C07F9/5728—Five-membered rings condensed with carbocyclic rings or carbocyclic ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Solid Fuels And Fuel-Associated Substances (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
NO921104A 1991-03-22 1992-03-20 Aminoguanidiner med farmasöytisk anvendelse, farmasöytiske preparater inneholdende disse forbindelser og deres anvendelse NO179171C (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB919106179A GB9106179D0 (en) 1991-03-22 1991-03-22 Improvements in or relating to organic compounds
GB919107927A GB9107927D0 (en) 1991-04-15 1991-04-15 Improvements in or relating to organic compounds

Publications (4)

Publication Number Publication Date
NO921104D0 NO921104D0 (no) 1992-03-20
NO921104L true NO921104L (no) 1992-09-23
NO179171B NO179171B (no) 1996-05-13
NO179171C NO179171C (no) 1996-08-21

Family

ID=26298625

Family Applications (1)

Application Number Title Priority Date Filing Date
NO921104A NO179171C (no) 1991-03-22 1992-03-20 Aminoguanidiner med farmasöytisk anvendelse, farmasöytiske preparater inneholdende disse forbindelser og deres anvendelse

Country Status (22)

Country Link
US (1) US5510353A (no)
EP (1) EP0505322B1 (no)
JP (1) JP2593022B2 (no)
KR (1) KR100198018B1 (no)
AT (1) ATE170838T1 (no)
AU (1) AU651442B2 (no)
CA (1) CA2063671C (no)
CZ (1) CZ284339B6 (no)
DE (1) DE69226894T2 (no)
DK (1) DK0505322T3 (no)
ES (1) ES2121836T3 (no)
FI (2) FI102371B (no)
HU (2) HUT64023A (no)
IE (1) IE920895A1 (no)
IL (1) IL101312A (no)
MX (1) MX9201244A (no)
MY (1) MY108158A (no)
NO (1) NO179171C (no)
NZ (1) NZ242069A (no)
RO (1) RO109194B1 (no)
SG (1) SG43221A1 (no)
SK (1) SK279214B6 (no)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0641198A1 (en) * 1992-05-23 1995-03-08 Smithkline Beecham Plc Medicaments for the treatment of anxiety
JPH07508276A (ja) * 1992-06-27 1995-09-14 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー ５−ｈｔ↓４受容体アンタゴニスト含有医薬品
GB9226537D0 (en) * 1992-12-21 1993-02-17 Smithkline Beecham Plc Compounds
GB9226532D0 (en) * 1992-12-21 1993-02-17 Smithkline Beecham Plc Compounds
JP3035818B2 (ja) * 1997-10-21 2000-04-24 日本精工株式会社 玉軸受
KR100364086B1 (ko) 1998-04-16 2002-12-11 도시바 라이텍쿠 가부시키가이샤 고압 방전등 및 조명 장치
ES2257869T3 (es) * 1998-08-21 2006-08-01 Novartis Ag Nueva formulacion oral para agonistas o antagonistas de 5-ht4.
RU2260424C9 (ru) * 1998-08-21 2006-05-20 Новартис Аг Новая композиция для перорального введения
TWI263496B (en) * 1999-12-10 2006-10-11 Novartis Ag Pharmaceutical combinations and their use in treating gastrointestinal disorders
US20040092511A1 (en) * 1999-12-10 2004-05-13 Billstein Stephan Anthony Pharmaceutical combinations and their use in treating gastrointestinal and abdominal viscera disorders
GB0019357D0 (en) 2000-08-07 2000-09-27 Melacure Therapeutics Ab Novel phenyl guanidines
GB0019359D0 (en) 2000-08-07 2000-09-27 Melacure Therapeutics Ab Novel guanidines
AU2002323776B2 (en) 2001-08-10 2008-07-31 Nippon Chemiphar Co., Ltd. Activator for peroxisome proliferator-responsive receptor Delta
JP4276074B2 (ja) 2001-10-12 2009-06-10 日本ケミファ株式会社 ペルオキシソーム増殖剤応答性受容体δの活性化剤
AU2003209114A1 (en) * 2002-02-14 2003-09-04 Wyeth Pyrrolylalkylidene-hydrazinecarboximidamide derivatives as 5-hydroxytryptamine-6 ligands
US6906095B2 (en) 2002-05-10 2005-06-14 Wyeth Indolylalkylidenehydrazine-carboximidamide derivatives as 5-hydroxytryptamine-6 ligands
US6951881B2 (en) 2002-05-10 2005-10-04 Wyeth (1-substituted-indol-3-yl) alkylidenehydrazinecarboximidamide derivatives as 5-hydroxytryptamine-6 ligands
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
ATE477268T1 (de) 2003-01-28 2010-08-15 Ironwood Pharmaceuticals Inc Zusammensetzungen zur behandlung von magen-darm- störungen
MY137386A (en) * 2003-07-24 2009-01-30 Novartis Ag Stable modifications of tegaserod hydrogen maleate
JP2007514000A (ja) * 2003-12-16 2007-05-31 テバ ファーマシューティカル インダストリーズ リミティド テガセロッド塩基及びその塩の多形現象形
US20060106086A1 (en) * 2004-04-26 2006-05-18 Santiago Ini Preparation of tegaserod and tegaserod maleate
WO2006002212A1 (en) * 2004-06-23 2006-01-05 Dr. Reddy's Laboratories Ltd. Tegaserod hemimaleate
WO2006045120A2 (en) * 2004-10-19 2006-04-27 Teva Pharmaceutical Industries Ltd. Purification of tegaserod maleate
RU2007132704A (ru) * 2005-01-31 2009-03-10 Новартис АГ (CH) Органические соединения
CZ298399B6 (cs) * 2005-05-02 2007-09-19 Zentiva, A. S. Zpusob prípravy 2-[(5-methoxy-1 H-indol-3-yl) methylen]-N-pentylkarbazimidamidu (tegaserodu)
WO2006116953A1 (en) * 2005-05-02 2006-11-09 Zentiva, A.S. A method for the preparation of tegaserod and slected salts thereof
JP2007145827A (ja) * 2005-10-27 2007-06-14 Teijin Pharma Ltd ベンゾ［ｂ］チオフェン誘導体およびその製造方法
GB0524668D0 (en) * 2005-12-02 2006-01-11 Novartis Ag Organic compounds
GB0601953D0 (en) * 2006-01-31 2006-03-15 Novartis Ag Organic compounds
ZA200809148B (en) 2006-04-18 2010-01-27 Nippon Chemiphar Co Activating agent for peroxisome proliferator activated receptor delta
CN100412059C (zh) * 2006-06-06 2008-08-20 江苏奥赛康药业有限公司 一种替加色罗的制备方法
AU2007316586A1 (en) * 2006-11-09 2008-05-15 Generics [Uk] Limited Novel process
EP1939176A1 (en) * 2006-12-22 2008-07-02 Novartis AG Salts of Tegaserod
WO2008149140A2 (en) * 2007-06-04 2008-12-11 Generics [Uk] Limited Tegaserod oxalate and polymorphic forms
WO2008149136A1 (en) * 2007-06-04 2008-12-11 Generics [Uk] Limited Tegaserod besylate and polymorphic forms
WO2008149137A2 (en) * 2007-06-04 2008-12-11 Generics [Uk] Limited Tegazerod benzoate and polymorphic forms
WO2008149139A2 (en) * 2007-06-04 2008-12-11 Generics [Uk] Limited Tegaserod fumarate and polymorphic forms
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
MX2009013293A (es) 2007-06-04 2010-02-15 Synergy Pharmaceuticals Inc Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos.
WO2008149138A1 (en) * 2007-06-04 2008-12-11 Generics [Uk] Limited Tegaserod malate and polymorphic forms
WO2008149154A2 (en) * 2007-06-05 2008-12-11 Generics [Uk] Limited Tegaserod succinate and polymorphic forms
US20090082419A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched tegaserod
WO2009053733A2 (en) 2007-10-24 2009-04-30 Generics [Uk] Limited Novel crystalline forms
WO2009053754A2 (en) 2007-10-24 2009-04-30 Generics [Uk] Limited Novel crystalline forms
WO2009053732A1 (en) 2007-10-24 2009-04-30 Generics [Uk] Limited Novel salt
WO2009053750A2 (en) 2007-10-24 2009-04-30 Generics [Uk] Limited Novel crystalline and amorphous forms
JP5474769B2 (ja) 2008-04-15 2014-04-16 日本ケミファ株式会社 ペルオキシソーム増殖剤活性化受容体の活性化剤
EP2810951B1 (en) 2008-06-04 2017-03-15 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
CA2730603C (en) 2008-07-16 2019-09-24 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
WO2010039429A1 (en) * 2008-09-19 2010-04-08 Cytokine Pharmasciences, Inc Guanylhydrazones for treatment of postoperative intestinal inflammation
JP6265583B2 (ja) 2008-10-17 2018-01-24 ウィスコンシン アルムニ リサーチ ファンデイション 生理活性アルファベータペプチドを作製する方法
WO2018129556A1 (en) 2017-01-09 2018-07-12 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
KR20170091783A (ko) 2008-12-31 2017-08-09 알데릭스, 인코포레이티드 체액 저류 또는 염 과부하와 연관된 장애 및 위장관 장애의 치료 시에 ｎｈｅ-매개된 역수송을 억제하는 화합물 및 방법
WO2011014520A2 (en) 2009-07-29 2011-02-03 Irm Llc Compounds and compositions as modulators of gpr119 activity
EA021275B9 (ru) 2009-09-03 2015-08-31 Байоэнердженикс Гетероциклические соединения, содержащая их фармацевтическая композиция и их применение для лечения pask-опосредованного заболевания
EA201200570A1 (ru) 2009-10-09 2012-11-30 Айрм Ллк Соединения и композиции в качестве модуляторов активности gpr119
US8394858B2 (en) 2009-12-03 2013-03-12 Novartis Ag Cyclohexane derivatives and uses thereof
US8697739B2 (en) 2010-07-29 2014-04-15 Novartis Ag Bicyclic acetyl-CoA carboxylase inhibitors and uses thereof
CN103402997B (zh) 2011-02-25 2015-08-26 柳韩洋行 二氨基嘧啶衍生物及其制备方法
EP2681207B1 (en) 2011-03-02 2016-12-28 Bioenergenix Heterocyclic compounds for the inhibition of pask
WO2014019092A1 (en) 2012-08-01 2014-02-06 The Hospital For Sick Children Inhibitors of peptidyl arginine deiminase (pad) enzymes and uses thereof
AU2013304812B2 (en) 2012-08-21 2016-06-09 Ardelyx, Inc. Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
US10376481B2 (en) 2012-08-21 2019-08-13 Ardelyx, Inc. Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
WO2014052619A1 (en) 2012-09-27 2014-04-03 Irm Llc Piperidine derivatives and compositions as modulators of gpr119 activity
EP2724723A1 (en) 2012-10-25 2014-04-30 Universitätsklinikum Hamburg-Eppendorf Tegaserod for use in the treatment of nerve injuries
JP2016514670A (ja) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド 他の薬物と組み合わせたグアニル酸シクラーゼ受容体アゴニスト
JP2016514671A (ja) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼのアゴニストおよびその使用
SMT201900386T1 (it) 2013-04-12 2019-09-09 Ardelyx Inc Composti nhe3-leganti e metodi per l'inibizione del trasporto di fosfato
KR101657616B1 (ko) 2013-05-24 2016-09-19 주식회사유한양행 피리미딘 고리를 포함하는 바이사이클릭 유도체 및 그의 제조방법
CN103467358B (zh) * 2013-08-15 2015-09-02 蚌埠丰原医药科技发展有限公司 马来酸替加色罗的制备方法
AU2018205400C1 (en) 2017-01-09 2026-01-15 Ardelyx, Inc. Compounds useful for treating gastrointestinal tract disorders
JP2020505333A (ja) 2017-01-09 2020-02-20 アルデリックス， インコーポレイテッド Ｎｈｅ媒介性アンチポートの阻害薬
US10278955B1 (en) * 2017-12-13 2019-05-07 Macau University Of Science And Technology Methods of treating cancer
TWI833113B (zh) * 2020-09-28 2024-02-21 日商日本精工股份有限公司 斜角滾珠軸承
CN112979528B (zh) * 2021-02-01 2023-02-28 青岛海洋生物医药研究院 一种替加色罗水溶性有机酸盐及其制备方法与应用
CN113845464B (zh) * 2021-10-28 2023-05-02 西安交通大学 一种吲哚胍类化合物及其制备方法和应用
CN113801052B (zh) * 2021-10-28 2023-06-27 西安交通大学 一种含有芳香酸酯的吲哚胍类化合物及其制备方法和应用
WO2023242102A1 (en) 2022-06-13 2023-12-21 KHR Biotec GmbH Novel ras inhibitors
EP4596561A1 (en) * 2022-10-27 2025-08-06 Suzhou Genhouse Bio Co., Ltd. Phosphorus-containing compound, pharmaceutical composition and use thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB842325A (en) * 1956-10-01 1960-07-27 Ici Ltd Pharmaceutical compositions containing aminoguanidine derivatives
GB842322A (en) * 1956-10-01 1960-07-27 Ici Ltd Aminoguanidine derivatives
GB842323A (en) * 1956-10-01 1960-07-27 Ici Ltd Aminoguanidine derivatives
GB842324A (en) * 1956-10-01 1960-07-27 Ici Ltd Aminoguanidine derivatives
US2855398A (en) * 1956-11-19 1958-10-07 Searle & Co Amidines of the indole series
US3317560A (en) * 1963-01-03 1967-05-02 Philips Corp Indol-3-yl alkylguanidine derivatives
DE3360148D1 (en) * 1982-02-10 1985-06-05 Beecham Group Plc Guanidine derivatives
US5095031A (en) * 1990-08-20 1992-03-10 Abbott Laboratories Indole derivatives which inhibit leukotriene biosynthesis
FR2669927B1 (fr) * 1990-11-29 1994-04-08 Adir Cie Nouveaux derives de guanidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.

Also Published As

Publication number Publication date
AU1309292A (en) 1992-09-24
KR920018055A (ko) 1992-10-21
DK0505322T3 (da) 1999-06-07
IL101312A (en) 1997-03-18
FI20010060A7 (fi) 2001-01-11
ATE170838T1 (de) 1998-09-15
AU651442B2 (en) 1994-07-21
IL101312A0 (en) 1992-11-15
CA2063671A1 (en) 1992-09-23
HK1011028A1 (en) 1999-07-02
NO179171B (no) 1996-05-13
FI102371B1 (fi) 1998-11-30
KR100198018B1 (ko) 1999-06-15
MY108158A (en) 1996-08-30
HU9200761D0 (en) 1992-05-28
HUT64023A (en) 1993-11-29
CZ284339B6 (cs) 1998-10-14
FI921222A0 (fi) 1992-03-20
EP0505322A1 (en) 1992-09-23
CA2063671C (en) 2005-03-15
RO109194B1 (ro) 1994-12-30
HU211510A9 (en) 1995-11-28
DE69226894D1 (de) 1998-10-15
NO921104D0 (no) 1992-03-20
NO179171C (no) 1996-08-21
FI102371B (fi) 1998-11-30
DE69226894T2 (de) 1999-02-18
NZ242069A (en) 1995-02-24
SG43221A1 (en) 1997-10-17
JP2593022B2 (ja) 1997-03-19
EP0505322B1 (en) 1998-09-09
JPH0586026A (ja) 1993-04-06
FI921222A7 (fi) 1992-09-23
FI20010060L (fi) 2001-01-11
SK279214B6 (sk) 1998-08-05
US5510353A (en) 1996-04-23
CS85892A3 (en) 1992-10-14
ES2121836T3 (es) 1998-12-16
MX9201244A (es) 1993-01-01
IE920895A1 (en) 1992-09-23

Similar Documents

Publication Publication Date Title
NO921104D0 (no) Farmasoeytisk aktive preparater, fremgangsmaate for deres fremstilling og anvendelse derav
MY101208A (en) Phenyl-piperazine anti-arrhythmia agents.
NO882608D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive pyrazolopyrideirer.
NO933452D0 (no) Et terapeutisk middel for parkinson's sykdom
DK0467248T3 (da) Pyrazolopyridinforbindelse og fremgangsmåder til fremstilling heraf
FI890689A0 (fi) 3-alkenyl-1-azabicyklo-/3.2.0/ -hept-2-en-2-karboxylsyrafoereningar.
HUT46313A (en) Process for producing 3/2h/-pyridazine derivatives and pharmaceutical compositions containing them as active components
NO881835L (no) Fremgangsmaate for fremstilling av terapeutisk aktive bicykliske forbindelser.
EP0285284A3 (en) N-phenethylaminoalkyl-benzamide anti-arrhythmia agents
DE69110217D1 (de) Derivate der Kaffeinsäure und sie enthaltende pharmazeutische Zusammensetzungen.
AU1093692A (en) Disubstituted ureas and thioureas derivatives
DK165878C (da) 3-substituerede-5-aminoalkyl-beta-carbolinderivater og fremgangsmaade til deres fremstilling

Legal Events

Date Code Title Description
MK1K Patent expired